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Population patterns of infection are determined largely by susceptibility to infection. Infection and vacci-
nation induce an immune response that, typically, reduces susceptibility to subsequent infections. With
a general epidemic model, we detect a ‘reinfection threshold’, above which reinfection is the principal
type of transmission and, consequently, infection levels are much higher and vaccination fails. The model
is further developed to address human tuberculosis (TB) and the impact of vaccination. The bacille
Calmette-Gue´rin (BCG) is the only vaccine in current use against TB, and there is no consensus about
its usefulness. Estimates of protection range from 0 to 80%, and this variability is aggravated by an
association between low vaccine efficacy and high prevalence of the disease. We propose an explanation
based on three postulates: (i) the potential for transmission varies between populations, owing to differ-
ences in socio-economic and environmental factors; (ii) exposure to mycobacteria induces an immune
response that is partially protective against reinfection; and (iii) this protection is not significantly improved
by BCG vaccination. These postulates combine to reproduce the observed trends, and this is attributed
to a reinfection threshold intrinsic to the transmission dynamics. Finally, we demonstrate how reinfection
thresholds can be manipulated by vaccination programmes, suggesting that they have a potentially power-
ful role in global control.
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1. INTRODUCTION
The invasion threshold for infectious pathogens has been a
keystone concept for many decades (Kermack & McKend-
rick 1927; Diekmann et al. 1990). Simply stated, if the aver-
age number of susceptible individuals infected by a single
infected individual is greater than one, then the infection
prevalence will increase. In a naive population, susceptibility
is at its maximum. Infection itself and vaccination both
reduce susceptibility to infection and disease. The simplest
assumption is that the immune response to primary infec-
tion provides a solid immunity to subsequent infections or
reinfections, and this gives rise to the susceptible–infected–
recovered (SIR) and susceptible–exposed–infected–
recovered (SEIR) frameworks (Anderson & May 1991).
The development of ideas about partial susceptibility
(or partial immune protection) has been driven largely by
considerations of interactions between various multistrain
pathogens (White et al. 1998; Ferguson & Andreasen
2002; Gomes et al. 2002) and of vaccine-escape mutants
(McLean 1995). Here, we extend these ideas to consider
the role of reinfection susceptibility in determining the
prevalence of infection. We develop a simple SIR model
where the recovered are partially susceptible to reinfec-
tion. We demonstrate that there is a reinfection threshold
above which the prevalence of infection reaches much
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higher levels. If a vaccine does not confer complete protec-
tion against reinfection, then it can interact with the trans-
mission dynamics to produce considerable variability in
vaccine outcome.
We apply the ideas to human tuberculosis (TB) and
vaccination with bacille Calmette-Gue´rin (BCG). Field
trials to evaluate BCG efficacy began in the 1930s, and
by the late 1950s the range of estimates was broad. Sub-
sequent trials have continued to record variable results
(Fine & Rodrigues 1990; Bloom & Fine 1994; Colditz et
al. 1994). Initial explanations of the observed variability
have invoked differences between vaccine strains, trial
methodology, host genetics and socio-economic con-
ditions. Another proposed explanation is that regional dif-
ferences in environmental mycobacteria (EM) might be
responsible for much of the observed variability (Palmer &
Long 1966; Fine 1995). The reasoning is that exposure
to EM imparts some degree of protection against Myco-
bacterium tuberculosis (Mtb), which is not improved by the
BCG vaccination, leading to an apparent absence of pro-
tection by the vaccine when trials are conducted in areas
of high EM exposure. In a sense, exposure to EM is acting
as a vaccination. This interference has been experimen-
tally demonstrated by studies in animal models (Palmer &
Long 1966; Edwards et al. 1982; Brandt et al. 2002) and,
more recently, by immuno-epidemiological field studies in
human populations (Black et al. 2002).
Geographical trends support the suggested influence of
EM on the outcome of vaccination. Namely, estimates of
BCG efficacy appear to increase with latitude, and
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geographical patterns of EM reveal higher prevalences at
lower latitudes (Palmer & Long 1966; Fine 1995). How-
ever, this argument does not explain the higher prevalence
of disease found at lower latitudes, just where immunity
induced by EM should be more common. How does Mtb
maintain high prevalence in those regions where the
majority of the population is ‘vaccinated’ by exposure to
EM?
A complementary observation is that immunity induced
either by a previous infection or by vaccine uptake does
not fully prevent reinfection (ten Dam & Pio 1982; van
Rie et al. 1999; Godfrey-Faussett et al. 2000; Smith et al.
2000). In this scenario, both the observed prevalence of
disease and the impact of vaccination programmes must
depend on the dynamic balance between primary infection
and reinfection rates, which, in turn, depend on all socio-
economic and environmental factors that affect trans-
mission (Lienhardt 2001).
We construct a simple mathematical model that repro-
duces the described trends. The model encapsulates three
postulates: (i) the potential for transmission varies
between populations; (ii) exposure to mycobacteria
induces an immune response that is partially protective
against reinfection; and (iii) this protection is not signifi-
cantly improved by vaccination.
2. BASIC MODEL STRUCTURE AND ANALYSIS
Before describing the dynamics of TB transmission we
extract some background results from a general SIR
framework, where those who have recovered from a pri-
mary infection or have been vaccinated have reduced sus-
ceptibility to infection:
dS
dt
= (1 v)  IS S,
dI
dt
= I(S  R)  (  )I ,
dR
dt
= v  I  IR  R. (2.1)
The variables S, I and R are the proportions of the popu-
lation susceptible, infected and recovered (with partial
immune protection), respectively; the life expectancy of
hosts at birth is 1/; the average duration of infectiousness
is 1/, and  is the transmission coefficient. The parameter
 (0    1) determines the degree of partial protection
given by a primary infection or vaccination:  = 0 implies
complete protection (i.e. the classic SIR model), and
 = 1 implies no protection (i.e. the susceptible–infected–
susceptible (SIS) model). The parameter v represents the
proportion of the population vaccinated at birth. The
model is built under the assumption that the mode of
action of acquired immunity is independent of whether
stimulation comes from infection or vaccination.
Without vaccination (v = 0), the basic reproduction
number is R0 = /(  ) (Diekmann et al. 1990).
Algebraic manipulation shows that the model has a single
stable non-trivial equilibrium above a first (invasion)
threshold (R0 = 1). At equilibrium, we have S
R = 1/R0, and the prevalence of infection (I ) is highly
sensitive to a second (reinfection) threshold (R0 = 1/).
When 1 R0  1/, most infections occur in naive suscep-
tibles (S ), but when R0 	 1/, most infections occur in the
previously infected (R) class, as this is generally larger and
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Figure 1. Two thresholds of transmission obtained from
model (2.1). The black line (R0 = 1) represents the invasion
threshold, above which infection persists in the host
population. The white line (R0 = 1/) represents the
reinfection threshold, where the prevalence of infection rises
steeply to much higher levels. The surface represents the
proportion of individuals that are infectious at equilibrium,
and this is coloured light grey below the reinfection
threshold, and dark grey above.
the infection potential is great enough to overcome the
immunity given by previous infection. Another view is that
R0 determines the model behaviour: for 1 R0 1/ the
model acts much as an SIR framework, and for R0 	 1/
the model demonstrates typical SIS behaviour. The two
thresholds are determined by the two parameters R0 and ,
as shown in figure 1: the black line represents the invasion
threshold, and the white line represents the reinfection
threshold. Below the invasion threshold, infection does not
persist, and above it there are two possibilities. Either the
proportion of infected individuals tends to a ‘low endemic
equilibrium’ (light-grey surface), or the level of infection
stabilizes at a ‘high endemic equilibrium’ (dark-grey
surface). Model (2.1) has been thoroughly analysed
(Gomes et al. (2004b), where the impact of vaccination is
also examined). Similar thresholds were obtained in the
context of multi-strain dynamics (Gomes et al. 2002, fig.
3a) where the ‘reinfection threshold’ gave rise to oscillatory
dynamics. Without further assumptions, the modelled vac-
cine can have very high efficacy below the reinfection thres-
hold and virtually no efficacy above it. This is highly
suggestive of what is happening with pulmonary TB.
3. TUBERCULOSIS MODEL STRUCTURE
A model for TB epidemiology must differentiate indi-
viduals according to their history of infection by Mtb. We
start by specifying four categories: S, susceptible individ-
uals, who have never encountered the mycobacterium; I,
infected individuals, who have active disease and are infec-
tious; L, latent individuals, who are infected but have not
developed active disease and are not infectious; and R,
recovered or cured individuals, who were previously
infected and have lost that infection. According to pre-
vious estimates (Vynnycky & Fine 1997), a proportion

 = 0.1 of infections progress to active TB, while the
remaining 0.9 maintain a latent infection. Latent and
recovered individuals have acquired some immunity,
which reduces the risk of subsequent infection, but does
 on 30 September 2009rspb.royalsocietypublishing.orgDownloaded from 
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Figure 2. Model for TB transmission dynamics. (a) Non-
vaccinated subpopulation. (b) Vaccinated subpopulation. All
parameters, except  and , are described in table 1. The
auxiliary parameter, , is 1 by default and this is changed
only to generate sub-models in figure 3.
not fully prevent it. Latent TB can progress to active TB
by either exogenous reinfection or endogenous reacti-
vation (at a rate ). Recovered individuals can revert to
active TB by exogenous reinfection only. The dynamics
of infection, immunity and treatment are described by the
diagram in figure 2a and formalized by the system of dif-
ferential equations
dS
dt
= (1 v)  S  S,
dI
dt
= 
(S  (R L)) L (  )I ,
dL
dt
= (1  
)(S  R)  
L  (  )L,
dR
dt
= I  (  )R. (3.1)
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These equations represent the rates of change of each
category and are expressed in terms of the parameters
described in table 1. Extra notations are , the auxiliary
parameter, which is 1 by default and permits the gener-
ation of sub-models in figure 3, and , the per capita rate
of infection, which is discussed further below. The model
is extended to incorporate vaccination at birth. This
requires the further specification of three categories: V,
vaccinated individuals who are not infected; and vacci-
nated individuals who have been infected and are either
infectious with active TB (IV) or latent (LV). Transmission
in the vaccinated population is described in figure 2b and,
using the parameters in table 1, this is formalized as
dV
dt
= v  IV  VV V,
dIV
dt
= 
V(V  LV)  LV  (  )IV,
dLV
dt
= (1  
)VV  
VLV  (  )LV. (3.2)
Three parameters require special attention. The first
refers to the rate of infection, , of a naive individual.
We make the usual assumption (Kermack & McKendrick
1927; Anderson & May 1991) that this rate is proportional
to the density of infectious individuals,  = (I  I V). The
constant of proportionality is the parameter , known as
the ‘transmission coefficient’. This parameter summarizes
all socio-economic and environmental factors that affect
transmission, and its variability reflects postulate (i). The
second refers to the rate of reinfection, , of an individual
who has previously been infected and has acquired some
degree of protective immunity. The parameter  is the fac-
tor reducing the risk of reinfection, and this is central to
postulate (ii). For the purposes of illustration, we fix
 = 0.25, but any value between 0 and 1 would lead to
the same conclusions. The third parameter, V, is the fac-
tor by which vaccination reduces the risk of reinfection,
and is initially assumed to be equal to , so fulfilling pos-
tulate (iii). The parameter V will be subsequently lowered
to illustrate the effect of vaccines that induce more protec-
tion than does the infection itself. Some authors state that
the principal effect of BCG is to reduce disease pro-
gression rather than the risk of actual infection (Smith et
al. 2000). This would correspond to introducing V as a
factor of 
 (and perhaps also ) rather than as a factor of
. Our results extend to these alternative assumptions.
4. TUBERCULOSIS RESULTS
Figure 3 describes the proportion of individuals with
active TB at equilibrium, in the absence of vaccination.
The full curve corresponds to the full model, and the
others result from two sub-models illustrating the contri-
butions of primary infection (dotted line) and reinfection
(dashed line). Applying standard methodology
(Diekmann et al. 1990) the basic reproduction number
associated with model (3.1) is calculated as
R0 =
(  
)
(  )(  )
,
and, in analogy with the basic SIR model described in
§ 2, the two thresholds for transmission are
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Table 1. Model parameters.
symbol definition value
 death rate and birth rate 1/70 yr1

 proportion of individuals that develop active TB. The remaining 1  
 have latent TB 0.1
 factor reducing the risk of infection as a result of acquired immunity to a previous 0.25
infection
V factor reducing the risk of infection as a result of vaccination 0.25; 0.20
v vaccination coverage 95%
 rate of endogenous reactivation of latent TB 0.0002 yr1
 rate of treatment of active TB 2 yr1
 transmission coefficient variable
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Figure 3. Two thresholds in TB transmission, in the absence
of vaccination. The full line represents the equilibrium
proportion of individuals with active TB as a function of the
transmission coefficient. The dotted line represents the
contribution of primary infection (model (3.1) with  = 0)
and is associated with the invasion threshold, 0 = (  )
(  )/(  
). The dashed line outlines the contribution
of reinfection (model (3.1) with  =  = 0.25) and is used to
mark the reinfection threshold, r = 0/. These two
processes are nonlinearly coupled in the full model (model
(3.1) with  = 1 and  = 0.25) to produce the full curve.
 = 0.0002.
invasion threshold (R0 = 1): 0 =
(  )(  )
  

,
reinfection threshold (R0 = 1/): r =
(  )(  )
(  
)
.
The invasion threshold indicates the minimum trans-
mission potential required for persistence of the infection
in the population, and the reinfection threshold is the
transmission potential above which reinfection dominates
the dynamics. For transmission coefficients between 0
and r, the majority of disease results from primary infec-
tion. For transmission coefficients greater than r, high
exposure overcomes protective immunity and the majority
of disease is caused by reinfection. As a result, the
prevalence of disease is relatively low for 0    r,
rising by two orders of magnitude near r to remain high
thereafter. A similar bimodal structure was recently dem-
onstrated in hepatitis B epidemiology as a result of a dif-
ferent mechanism (Medley et al. 2001).
Proc. R. Soc. Lond. B (2004)
Figure 4 shows the effect of a vaccination programme:
95% coverage with a vaccine that protects as much as a
previous infection (V = ). The full curves in figure 4a
show the proportions of individuals with active TB at
equilibrium: the higher curve refers to the absence of vac-
cination, as in figure 3, and the lower curve corresponds
to the presence of vaccination. The three dots (marked A,
B, C) represent model populations with different trans-
mission coefficients, used to simulate the impact of vacci-
nation over time (figure 4b). The proportion of cases
prevented by the vaccination programme is shown in fig-
ure 4c. The variability in vaccination impact is evident: it
ranges from highly effective at low prevalences (population
A) to having a negligible effect at high prevalences
(population C). A vaccine that protects only as well as a
previous infection will have no practical effect unless the
transmission coefficient is below the reinfection threshold,
r. Similarly, interference with EM would have no notice-
able impact on populations whose transmission coef-
ficients are above r, but it could contribute to a
significant reduction in TB incidence in populations with
lower transmission coefficients.
So far we have assumed that infection and vaccination
induce equivalent immune responses but this is unlikely
to be exactly so. If the vaccine reduces susceptibility by a
factor V  , then the transmission threshold for vaccine
protection is rV = (/V)r. A vaccine with a reduced effi-
cacy (V 	 ) fails to be protective when the transmission
coefficient is above rV, which is lower than r. For a
reasonable range of V values, the overall impact of such
a vaccine would be similar to that represented in figure 4.
In particular, the variable efficacy discussed for V = 
extends to the case V 	 . This is generally accepted as
the BCG scenario.
The most exciting and optimistic results are those for
a vaccine efficacy greater than the protection induced by
infection (V  ). Such a vaccine would increase the
reinfection threshold and consequently enlarge the range
of populations where vaccination can reach high efficacy
(see figure 5). This is most evident for population C,
where vaccines discussed previously (V  ) registered
efficacies close to nil, and in which the new vaccine can
reduce the prevalence of active TB by more than two
orders of magnitude. The reinfection threshold can be
manipulated by appropriate vaccines and, if carefully
quantified, it can play a key role in setting targets for
future vaccine performance and use.
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Figure 4. The impact of vaccination, given that the
protective effect of the vaccine does not exceed that of
acquired immunity to a previous infection (V = ).
(a) Proportions of individuals with active TB at equilibrium,
before and after implementation of a mass vaccination
programme with 95% coverage. The dashed line represents
the ideal scenario of 100% vaccination coverage, and is
equivalent to that obtained from the reinfection sub-model
in figure 3. The three dots (marked A, B, C) illustrate the
pre-vaccination equilibria of three model populations
(V = 0.25). (b) Simulation of the effects of mass vaccination
on the three model populations. The prevalence of disease,
I(t)  I V(t), gradually decreases towards the post-vaccination
equilibrium. (c) Proportion of cases prevented by the
vaccination programme, 1  (I (t) IV(t))/(I(0)  IV(0)), as a
function of time. Time is measured in years, and the
beginning of vaccination is set at t = 0.
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Figure 5. Impact of a vaccine that is more potent than a
previous infection (V  ). The solid curves represent the
proportion of individuals with active TB before (higher
curve) and after (lower curve) the implementation of a
vaccination programme. The vaccination coverage is 95%
and the susceptibility reduction factor is V = 0.20. The
dashed lines represent the ideal scenario of 100% coverage:
the lower curve corresponds to V = 0.20, while the higher
corresponds to V = 0.25 as in figure 4, and is repeated here
for comparison.
5. DISCUSSION
Using a minimal model for transmission dynamics, we
have demonstrated that three well-accepted postulates
generate the dominant trends in TB epidemiology. To our
knowledge, this is the first model to explain, simul-
taneously, the apparent variabilities in BCG vaccination
efficacy and TB prevalence. Furthermore, we demonstrate
that the two variabilities act synergistically, and are there-
fore inseparable. We have shown how reinfection can be
a major promoter of variability in TB incidence, and how
this interferes with an individual’s response to vaccination.
Although the variabilities are promoted by nonlinearities
in the population dynamics of infection and reinfection,
the predicted variable efficacy of the vaccine will be appar-
ent in individual measurements. For example, BCG is
expected to confer more protection to an individual in the
UK than to an individual in a highly endemic region,
because exposure to Mtb interferes with BCG and reduces
its efficacy (Smith et al. 2000). This fundamental aspect
of TB epidemiology has not been captured by previous
models, as they have not fully implemented reinfection
(Blower et al. 1995, 1996; Dye et al. 1998; Dye &
Williams 2000) or vaccination (Vynnycky & Fine 1997).
The model was then used to discuss prospects for con-
trol. At this stage, agreement between model output and
epidemiological data is restricted to broad trends.
Enhanced accuracy requires the incorporation of further
complexities into the model, and the treatment of hetero-
geneities in field data and trial design (Sutherland et al.
1982; Styblo 1991; Comstock 1994). In particular, meas-
ures of immune protection (here represented by  and V )
are crucial players and deserve special care. Effective
immunity results from the interaction of various mech-
anisms (Smith et al. 1984). It has been debated whether
immunity confers some protection to all individuals,
reducing their susceptibility by a factor  (‘partial’
immunity), or immunity confers full protection to some
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individuals, leaving a fraction  unprotected (‘all-or-
nothing’ immunity). It is also argued that immunity
induced by the BCG vaccine wanes over time (‘temporary’
immunity). The real scenario is likely to combine the three
mechanisms, and the development of models that con-
sider the dynamics of immunity more deeply can be
illuminating. In the meantime, we have demonstrated that
partial protection promotes variability, and this should
extend to more complex mechanisms of immunity that
involve partial protection.
TB is widespread and requires global control measures.
As past empirical experience has shown, and the present
theory explains, a major difficulty lies in achieving a sig-
nificant impact in those regions where the disease preva-
lence is high owing to reinfection ( 	 r). Reducing
transmission can have a significant impact on TB preva-
lence, especially if it is brought below the reinfection thres-
hold. This is probably what the developed world
experienced from the mid-1800s until the 1970s, owing
to major improvements in socio-economic conditions.
However, in less developed countries this is a difficult and
slow process. The development of more potent vaccines
against TB is a hopeful possibility (Britton & Palendira
2003; Olsen & Andersen 2003; Reed et al. 2003). In the
meantime, the most immediate measure to keep TB under
control is the rapid detection and treatment of active TB
cases (Dye et al. 1998; Dye & Williams 2000; World
Health Organization 2002). A recent extension to this
approach is to identify and treat persons with latent infec-
tion to prevent the development of active disease. This
substantial shift in management is vigorously implemented
in the USA (Small & Fujiwara 2001), and its extension to
other regions of the world is being debated (Chaisson
2000). Again, variable outcomes emerge as a result of vari-
able reinfection rates (Gomes et al. 2004a). The success
of detect-and-treat programmes will be determined largely
by characteristics of the target population and by the com-
parative susceptibility of those who are latent and those
who have recovered.
In conclusion, understanding reinfection is fundamental
to understanding TB epidemiology, to exploring the avail-
able options for control and to guiding the development of
new interventional tools. These conclusions are not only
relevant to TB but more generally applicable to diseases
characterized by recurrence of infection. The reinfection
threshold is a concept introduced here to represent the
transmissibility required to promote recurrent infections.
Populations that exceed this threshold sustain high levels
of infection and tend to be insensitive to interventions.
Finally, and most excitingly, reinfection thresholds can be
manipulated by interventions, providing new hope for the
control of infectious disease in high-burden regions.
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